Ruben A. Mesa spends much of his time researching Myelofibrosis, Internal medicine, Surgery, Myeloid and Polycythemia vera. His Myelofibrosis research is multidisciplinary, incorporating perspectives in Essential thrombocythemia, Adverse effect and Anemia. His work deals with themes such as Gastroenterology and Oncology, which intersect with Internal medicine.
His Surgery research focuses on Splenectomy and how it relates to Perioperative. The concepts of his Myeloid study are interwoven with issues in Metaplasia, Myeloid leukemia, Bone marrow and Thrombocytosis. His Polycythemia vera study incorporates themes from European LeukemiaNet and Intensive care medicine.
His main research concerns Internal medicine, Myelofibrosis, Polycythemia vera, Ruxolitinib and Essential thrombocythemia. His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine. Ruben A. Mesa combines subjects such as Myeloid, Anemia and Constitutional symptoms with his study of Myelofibrosis.
Within one scientific family, Ruben A. Mesa focuses on topics pertaining to Transplantation under Polycythemia vera, and may sometimes address concerns connected to Stem cell. His work in Ruxolitinib addresses subjects such as Adverse effect, which are connected to disciplines such as Discontinuation. Ruben A. Mesa has researched Essential thrombocythemia in several fields, including Bone pain and Acute leukemia.
His primary areas of study are Internal medicine, Myelofibrosis, Ruxolitinib, Oncology and Gastroenterology. When carried out as part of a general Internal medicine research project, his work on Myeloproliferative neoplasm, Polycythemia vera, Essential thrombocythemia and Quality of life is frequently linked to work in In patient, therefore connecting diverse disciplines of study. His Myelofibrosis research includes elements of Spleen, Anemia, Transplantation and Constitutional symptoms.
His Ruxolitinib study combines topics from a wide range of disciplines, such as Previously treated, Janus kinase inhibitor, Tolerability and Phases of clinical research. Ruben A. Mesa usually deals with Oncology and limits it to topics linked to Cytopenia and Surrogate endpoint. Ruben A. Mesa studied Gastroenterology and Adverse effect that intersect with Discontinuation.
His primary areas of investigation include Internal medicine, Myelofibrosis, Ruxolitinib, Gastroenterology and Cohort. His Internal medicine study frequently links to adjacent areas such as Oncology. Myelofibrosis is a subfield of Bone marrow that Ruben A. Mesa investigates.
His Ruxolitinib research integrates issues from Thrombocytosis, Cancer research, Cell and Phases of clinical research. As a part of the same scientific study, Ruben A. Mesa usually deals with the Gastroenterology, concentrating on Stem cell and frequently concerns with Toxicity and Combination therapy. His Cohort research incorporates themes from Cancer, Clinical endpoint, Clinical trial, Absolute neutrophil count and Chemotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert.
Cancer Cell (2005)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy.
The New England Journal of Medicine (2012)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani.
The New England Journal of Medicine (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti.
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr.
The Lancet (2020)
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman.
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes.
Journal of Clinical Oncology (2011)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka.
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi;Jean Jacques Kiladjian;Martin Griesshammer;Tamas Masszi.
The New England Journal of Medicine (2015)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi;A. Pardanani;K. H. Lim;K. H. Lim;O. Abdel-Wahab.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: